Researchers at Vanderbilt University Medical Center, including Department of Medicine Drs. Alex Bick (senior author), Brett Heimlich, Brent Ferrell, Ashwin Kishtagari and Michael Savona, have identified key factors that contribute to the clonal growth of abnormal blood cells experienced by roughly one in 10 people over age 70.
Eleven current Vanderbilt University faculty members are included in the 2024 list of “Highly Cited Researchers” around the world whose papers have been cited most frequently by other scientists.
Information was gathered by investigators with the Reproductive Health After Cancer Diagnosis and Treatment (REACT) study, an initiative led by Andreana Holowatyj, PhD, MSCI, Assistant Professor of Medicine, Division of Epidemiology.
The panel determined that allowing the wider indication would put patients at risk for adverse reactions from the two immunotherapies but without the added benefit in survival.
The V Foundation for Cancer Research has awarded a $600,000 grant to Tae Kon Kim, MD, PhD, assistant professor of Medicine (Hematology and Oncology). Kim and colleagues will study whether this protein hinders the ability of the immune system to fight MDS and whether it can be blocked to treat MDS.
In this new position Cathy Eng, MD (Hematology and Oncology), the David H. Johnson Professor of Surgical and Medical Oncology, will elevate Vanderbilt-Ingram’s profile locally, regionally, nationally and internationally through stakeholder engagement, programmatic development and targeted marketing.
Interim results are promising from on ongoing phase 1 clinical trial testing an allogeneic or “off-the-shelf” chimeric antigen receptor Tcell (CAR T) therapy for patients with multiple myeloma who have not responded to existing treatments or who have relapsed.
A cancer vaccine that had little success in clinical trials for patients with advanced tumors could potentially have efficacy if administered earlier in the treatment cycle, according to a study from Vanderbilt researchers.
Jennifer Lewis, MD, MPH, and Lucy Spalluto, MD, MPH, are the recipients of the 2024 VAQS Team Award for work they began in 2017.
The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.
